New hope for tough schizophrenia cases: Brain-Targeting combo therapy enters testing
NCT ID NCT06574360
Summary
This study is testing whether adding a second brain-targeting drug to an experimental treatment works better for schizophrenia that hasn't responded well to standard medications. It will involve 90 adults whose schizophrenia symptoms persist despite trying at least two different antipsychotics. Participants will take their usual medication plus either the two-drug combination or the experimental drug with a placebo for 12 weeks to see which group shows greater improvement in symptoms, thinking skills, and daily function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Psychiatry, China Medical University Hospital
RECRUITINGTaichung, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.